Get it on Google Play

Milestone Pharmaceuticals enrolls first European patient in AFib trial

October 9, 2026 8:00 AM EDT Send to a Friend
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) announced that the first European participant has been enrolled in its ReVeRA-301 Phase 3 clinical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login